Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy
Ferah Cömert Önder, Pınar Si̇yah, Serdar Durdağı, Mehmet Ay, Bülent Özpolat
Abstract
Eukaryotic elongation factor 2 kinase (eEF2K) has been shown to be an important molecular driver of tumorigenesis and validated as a potential novel molecular target in various solid cancers including triple negative breast cancer (TNBC).
Topics & Concepts
Eukaryotic translation elongation factor 1 alpha 1Elongation factorEtodolacElongationTriple-negative breast cancerCancer researchKinaseTargeted therapyCarcinogenesisCancerChemistryBiologyBreast cancerCell biologyBiochemistryMaterials scienceGeneticsGeneMetallurgyRNAUltimate tensile strengthRibosomeMicrobial Natural Products and BiosynthesisUbiquitin and proteasome pathwaysEstrogen and related hormone effects